Clinical Medicine Division, Korea Institute of Oriental Medicine, Daejeon, Korea.
Future Medicine Division, Korea Institute of Oriental Medicine, Daejeon, Korea.
Clin Otolaryngol. 2019 Nov;44(6):997-1003. doi: 10.1111/coa.13425. Epub 2019 Oct 29.
The aim of the current study was to investigate the effectiveness and clinical feasibility of Biyeom-go for the treatment of nasal symptoms associated with rhinitis.
Prospective observational study.
This study was conducted at the Woosuk Korean Medicine Medical Center in South Korea.
Fifty-eight patients with rhinitis participated in this study. All patients received Biyeom-go treatment >3 times daily for a total of 4 weeks.
The primary outcome was the total nasal symptom score. Mini-rhinoconjunctivitis quality of life questionnaire, nasal endoscopy index, total serum immunoglobulin E levels and immunologic factors in nasal lavage fluid were also measured.
Biyeom-go administration was associated with significant improvements in total nasal symptoms scores (P < .0001) and mini-rhinoconjunctivitis quality of life questionnaire scores (P < .0001) in a time-dependent manner. The nasal endoscopy index also significantly improved at weeks 2 (P = .0049), 3 (P < .0001) and 4 (P = .0001) after Biyeom-go treatment. Significantly, increased interleukin-2 levels (P = .005) and decreased interleukin-8, chemokine (C-C motif) ligand (CCL) 5, chemokine (C-X-C motif) ligand (CXCL) 9, CCL2 and CXCL10 levels were observed in the nasal lavage fluid.
The present findings suggest that Biyeom-go may be beneficial for the management of rhinitis symptoms and rhinitis-associated quality of life. Further well-designed randomised controlled trials are needed to evaluate the effectiveness of Biyeom-go for rhinitis.
本研究旨在探讨鼻渊合剂治疗鼻炎相关鼻部症状的有效性和临床可行性。
前瞻性观察性研究。
本研究在韩国全州吾苏 Korean Medicine 医疗中心进行。
58 例鼻炎患者参与本研究。所有患者均接受鼻渊合剂治疗,每日>3 次,共 4 周。
主要结局指标为总鼻部症状评分。还测量了迷你鼻结膜炎生活质量问卷、鼻内镜指数、总血清免疫球蛋白 E 水平以及鼻灌洗液中的免疫因子。
鼻渊合剂给药与总鼻部症状评分(P<.0001)和迷你鼻结膜炎生活质量问卷评分(P<.0001)的显著改善呈时间依赖性相关。鼻内镜指数在治疗后第 2、3、4 周也显著改善(P=.0049、P<.0001、P=.0001)。此外,鼻灌洗液中白细胞介素-2 水平升高(P=.005),白细胞介素-8、趋化因子(C-C 基序)配体(CCL)5、趋化因子(C-X-C 基序)配体(CXCL)9、CCL2 和 CXCL10 水平降低。
本研究结果提示鼻渊合剂可能有助于改善鼻炎症状和鼻炎相关生活质量。需要进一步设计良好的随机对照试验来评估鼻渊合剂治疗鼻炎的疗效。